RecruitingNCT01574053
Neurological
Juvenile Huntington disease
1
studies recruiting now
as of 7 Sept 2026
4
studies registered in total
as of 7 Sept 2026
20
countries with a recruiting site
as of 7 Sept 2026
10 Apr 2012
most recent study posted
among recruiting studies
Recruiting trials
Showing the 1 most recently updated recruiting study, as recorded 7 Sept 2026. Live status on each study page.
Search all Juvenile Huntington disease studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Juvenile Huntington disease study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Juvenile Huntington disease
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the gene involved (HTT).
Treatments being studied
6 approved treatments and 47 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Tetrabenazine (Nitoman)Approved: Lisdexamfetamine Dimesylate (Elvanse)Approved: Deutetrabenazine (Austedo)Approved: Atomoxetine Hydrochloride (Atomoxetine hydrochloride)Approved: Guanfacine Hydrochloride (Akfen)Approved: Methylphenidate Hydrochloride (Adhansia xr)
Phase 3Valbenazine
Phase 3Riluzole (Exservan)
Phase 3Metformin
Phase 3Creatine
Phase 3Dalzanemdor
Phase 3Pridopidine (Huntexil)
Phase 3Ubidecarenone
Phase 3Tominersen
+ 39 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).